Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?

Immune checkpoint inhibitors represent a major therapeutic advance in non-small-cell lung cancer with several approved anti-programmed death-1 and anti-programmed death-L1 immunotherapies. A majority of patients however, will not respond to immune checkpoint inhibitors and display primary resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Pourmir, Ivan, Gazeau, Benoit, de Saint Basile, Hortense, Fabre, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992482/
https://www.ncbi.nlm.nih.gov/pubmed/35582440
http://dx.doi.org/10.20517/cdr.2020.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992482/
https://www.ncbi.nlm.nih.gov/pubmed/35582440
http://dx.doi.org/10.20517/cdr.2020.14

Ejemplares similares